Recommended articles Clinical Impact of Semaglutide, a Glucagon-Like Peptide-1 Receptor Agonist, on Obesity Management: A Review Alorfi NM, Algarni AS Clinical Pharmacology: Advances and Applications 2022, 14:61-67 Published Date: 3 August 2022 Clinical Insight on Semaglutide for Chronic Weight Management in Adults: Patient Selection and Special Considerations Chao AM, Tronieri JS, Amaro A, Wadden TA Drug Design, Development and Therapy 2022, 16:4449-4461 Published Date: 29 December 2022 Managing Severe Hypoglycaemia in Patients with Diabetes: Current Challenges and Emerging Therapies Demirbilek H, Vuralli D, Haris B, Hussain K Diabetes, Metabolic Syndrome and Obesity 2023, 16:259-273 Published Date: 27 January 2023 The Characteristics, Mechanisms and Therapeutics: Exploring the Role of Gut Microbiota in Obesity Zhuang Z, Zhou P, Wang J, Lu X, Chen Y Diabetes, Metabolic Syndrome and Obesity 2023, 16:3691-3705 Published Date: 20 November 2023 The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects Jensen TL, Brnden A, Karstoft K, Sonne DP, Christensen MB Patient Preference and Adherence 2024, 18:373-382 Published Date: 8 February 2024
Fat Mass Retatrutide works by engaging multiple hormone pathways that regulate appetite and metabolism
You're already on tirzepatide and it's working, so should you switch to retatrutide
The American Diabetes Association now recommends GLP-1 RAs for patients with established ASCVD regardless of their A1C and regardless of if the patient is taking metformin, the historically first line medication for T2DM [38]
